NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$18.0b

Last Updated

2021/05/17 23:02 UTC

Data Sources

Company Financials +

Executive Summary

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. More Details


Snowflake Analysis

Excellent balance sheet with solid track record.


Similar Companies

Share Price & News

How has Bio-Rad Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: BIO's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-2.3%

BIO

-0.8%

US Life Sciences

-0.6%

US Market


1 Year Return

25.1%

BIO

41.9%

US Life Sciences

46.0%

US Market

Return vs Industry: BIO underperformed the US Life Sciences industry which returned 45.7% over the past year.

Return vs Market: BIO underperformed the US Market which returned 50.8% over the past year.


Shareholder returns

BIOIndustryMarket
7 Day-2.3%-0.8%-0.6%
30 Day-5.8%-5.7%-1.8%
90 Day-9.2%-8.7%0.2%
1 Year25.1%25.1%42.1%41.9%48.4%46.0%
3 Year101.8%101.8%101.4%100.3%60.5%50.4%
5 Year309.1%309.1%204.3%200.5%125.9%100.9%

Long-Term Price Volatility Vs. Market

How volatile is Bio-Rad Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bio-Rad Laboratories undervalued compared to its fair value and its price relative to the market?

4.28x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BIO ($589.74) is trading above our estimate of fair value ($406.66)

Significantly Below Fair Value: BIO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BIO is good value based on its PE Ratio (4.3x) compared to the US Life Sciences industry average (44.4x).

PE vs Market: BIO is good value based on its PE Ratio (4.3x) compared to the US market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: BIO's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: BIO is good value based on its PB Ratio (1.7x) compared to the US Life Sciences industry average (6.8x).


Future Growth

How is Bio-Rad Laboratories forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-44.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIO's earnings are forecast to decline over the next 3 years (-44.3% per year).

Earnings vs Market: BIO's earnings are forecast to decline over the next 3 years (-44.3% per year).

High Growth Earnings: BIO's earnings are forecast to decline over the next 3 years.

Revenue vs Market: BIO's revenue (3.6% per year) is forecast to grow slower than the US market (9% per year).

High Growth Revenue: BIO's revenue (3.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIO's Return on Equity is forecast to be low in 3 years time (4.4%).


Past Performance

How has Bio-Rad Laboratories performed over the past 5 years?

65.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIO has a high level of non-cash earnings.

Growing Profit Margin: BIO's current net profit margins are higher than last year (67.8%).


Past Earnings Growth Analysis

Earnings Trend: BIO's earnings have grown significantly by 65.4% per year over the past 5 years.

Accelerating Growth: BIO's earnings growth over the past year (159.5%) exceeds its 5-year average (65.4% per year).

Earnings vs Industry: BIO earnings growth over the past year (159.5%) exceeded the Life Sciences industry 19.5%.


Return on Equity

High ROE: BIO's Return on Equity (38.6%) is considered high.


Financial Health

How is Bio-Rad Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: BIO's short term assets ($2.2B) exceed its short term liabilities ($609.9M).

Long Term Liabilities: BIO's short term assets ($2.2B) do not cover its long term liabilities ($2.7B).


Debt to Equity History and Analysis

Debt Level: BIO's debt to equity ratio (0.01%) is considered satisfactory.

Reducing Debt: BIO's debt to equity ratio has reduced from 16.6% to 0.01% over the past 5 years.

Debt Coverage: BIO's debt is well covered by operating cash flow (50535.1%).

Interest Coverage: BIO earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Bio-Rad Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Norman Schwartz (70 yo)

18.33yrs

Tenure

US$7,992,423

Compensation

Mr. Norman D. Schwartz has been the Chief Executive Officer and President of Bio-Rad Laboratories, Inc. since January 1, 2003 and has been its Chairman since 2012. Mr. Schwartz served as Vice President of ...


CEO Compensation Analysis

Compensation vs Market: Norman's total compensation ($USD7.99M) is about average for companies of similar size in the US market ($USD11.20M).

Compensation vs Earnings: Norman's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BIO's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: BIO's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BIO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bio-Rad Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bio-Rad Laboratories, Inc.
  • Ticker: BIO
  • Exchange: NYSE
  • Founded: 1952
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$18.038b
  • Shares outstanding: 29.76m
  • Website: https://www.bio-rad.com

Number of Employees


Location

  • Bio-Rad Laboratories, Inc.
  • 1000 Alfred Nobel Drive
  • Hercules
  • California
  • 94547
  • United States

Listings


Biography

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers produ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/17 23:02
End of Day Share Price2021/05/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.